Yelena Y. Janjigian, MD - Moving the Treatment of Advanced Gastroesophageal Cancers Forward: How Can We Maximize the Benefits of Novel Immunotherapy Approaches?


Manage episode 337276214 series 103590
Player FM과 저희 커뮤니티의 PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education 콘텐츠는 모두 원 저작자에게 속하며 Player FM이 아닌 작가가 저작권을 갖습니다. 오디오는 해당 서버에서 직접 스트리밍 됩니다. 구독 버튼을 눌러 Player FM에서 업데이트 현황을 확인하세요. 혹은 다른 팟캐스트 앱에서 URL을 불러오세요.
Go online to to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recently approved immunotherapy options have revolutionized the treatment of patients with advanced gastroesophageal cancers (eg, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma, esophageal squamous cell carcinoma [ESCC]), which have traditionally been associated with poor outcomes due to late detection, high heterogeneity, and limited response to chemotherapy and targeted treatments. With clinical trials validating the efficacy of immune checkpoint inhibition across multiple lines of therapy and regardless of PD-L1 expression, nivolumab and pembrolizumab have become standards of care in the frontline setting as part of various combinations, and nivolumab monotherapy has been approved in patients with ESCC after previous chemotherapy. Recently, nivolumab plus ipilimumab became the first chemotherapy-free combination to gain approval for frontline use in patients with ESCC. In light of these treatment advances, do you know how to select among the different immunotherapy options and determine the best therapeutic approach for each of your patients with advanced gastroesophageal cancers? Hear from the experts on which biomarkers and other factors are/are not helpful in guiding clinical decisions, and how you can bring your patients the latest cutting-edge therapies backed by robust evidence. Also, learn from illustrative cases discussed by the faculty on how to apply the current data to practice. Upon completion of this activity, participants should be better able to: Identify patients with advanced gastroesophageal cancers (ie, gastric, GEJ, or esophageal cancer) who may benefit from recently approved immunotherapy options based on efficacy and safety evidence; Incorporate recently approved immunotherapy options into treatment plans for eligible patients with advanced gastroesophageal cancers across multiple lines of therapy; and Apply a team approach to optimize the use of immunotherapy, including strategies to promptly recognize and manage immune-related adverse event, in patients with advanced gastroesophageal cancers.

508 에피소드